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ABSTRACT 
Objective: To develop a simple and cost effective chiral HPLC method for the separation of citalopram (CIT) enantiomers using chiral mobile phase 
additives (CMPAs). 
Methods: Sulfated beta cyclodextrin (S-β-CD) was synthesized in our laboratory and was evaluated as a CMPA. The parameters affecting the 
resolution were optimized. CIT enantiomers were resolved on an achiral Kromasil C8 column (150 mm × 4.6 mm, 5 µm) using methanol and 20 mM 
KH2PO4
Results: Synthesized S-β-CD gave a better resolution than the marketed form. This method was validated as per ICH guidelines and was found to 
comply with the standard norms. A good linearity was observed in the concentration range of 1-30 µg/ml with R
 (pH 3) containing 12 mM S-β-CD (35:65) as the mobile phase with a flow rate of 1 ml/min at 240 nm. Chiral resolution capacity of 
synthesized S-β-CD was compared to the marketed product. The method using synthesized S-β-CD as CMPA was validated and applied for the 
quantitative determination of CIT enantiomers in bulk drug and tablet formulation.  
2
Conclusion: A rapid and cost effective RP-HPLC method was developed and validated as per ICH guidelines to separate the CIT enantiomers. The 
method could be successfully applied for the quantitative determination of CIT enantiomers in bulk drug samples and pharmaceutical formulations.  
= 0.9993 for both enantiomers. 
The limit of detection and limit of quantification was 0.0272 and 0.0824 μg/ml for the R-enantiomer and 0.0303 and 0.0920 μg/ml for the S-
enantiomer respectively.  
Keywords: Enantiomeric resolution, Citalopram enantiomers, Citalopram enantiomeric purity, Chiral additive. 
 
INTRODUCTION 
Citalopram, (CIT) chemically known as ((RS)-1-[3-(dimethylamino) 
propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile), is 
a potent and highly selective serotonin reuptake inhibitor that is 
primarily prescribed for the treatment of depression and other 
central nervous system diseases, such as anxiety disorder, panic 
disorder, obsessive–compulsive disorder, social phobia or post-
traumatic stress disorder [1]. The drug was initially marketed in its 
racemic form. Preclinical studies have postulated that escitalopram 
(SCIT) is more efficacious than racemic CIT and about 150-times 
more potent than the R-citalopram (RCIT), which was initially 
assumed to be pharmacologically inactive, but is currently known to 
counteract the action of the SCIT without causing pharmacokinetic 
interactions [2-4]. Hence SCIT is now also marketed as a single 
enantiomer. The structure of SCIT is shown in fig. 1. 
 
 
Fig. 1: Structure of escitalopram 
 
The US Food and Drug Administration and other regulatory agencies 
have made it mandatory for the manufacturers to investigate each 
enantiomer of the chiral drug individually [5]. According to the 
International Conference on Harmonization (ICH) guidelines, chiral 
identity, enantiomeric impurity and chiral assay tests may be needed 
in drug substance and product specifications [6]. 
Chiral HPLC is a widely used technique for the determination of 
optical purity in bulk drugs and formulations. Chiral HPLC methods 
may either be direct, which utilize chiral stationary phases (CSPs) or 
chiral mobile phase additives (CMPAs), or indirect, which involve 
derivatization of samples. HPLC methods based on CMPAs offer the 
advantages of flexibility with a wide range of possible additives 
available and lower cost compared to the equivalent CSP. The use of 
chiral additives in the mobile phase provides a good alternative to 
expensive chiral columns because enantiomeric separation can be 
carried out using conventional achiral columns which have higher 
efficiencies and are less expensive compared to chiral columns [7]. 
Chiral HPLC is more challenging since enantiomers elute together, 
except in a chiral environment. 
Cyclodextrins and their derivatives are one of the most widely used 
chiral additives in the mobile phase, which provide a cost effective 
alternative to relatively expensive CSPs [8, 9]. Cyclodextrins 
separate the enantiomers utilizing the phenomenon of host guest 
complexation. The affinity of the analyte for cyclodextrin is due to 
the hydrophobic interaction between the analyte and the 
cyclodextrin cavity and the hydrogen bonding between the analyte 
and the functional groups on the cyclodextrin ring. Derivatization of 
cyclodextrin not only increases the aqueous solubility but also 
changes the chiral recognition and hydrogen bonding capabilities of 
the native cyclodextrin.  
There are reports of separation of CIT enantiomers using liquid 
chromatography, the majority of which employ CSPs [10-15] and beta 
cyclodextrin (β-CD) as CMPA on a cyanopropyl column [16]. Capillary 
electrophoretic methods have been reported where chiral selectors 
were added to the background electrolyte [17-19]. Enantioselective 
extraction of SCIT using a chiral imprinted polymer is also reported 
[20]. Semi-preparative separation of SCIT has been established with a 
CSP using supercritical fluid chromatography [21].  
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Sulfated beta cyclodextrin (S-β-CD), an anionic derivative of β-CD, is 
known to provide better resolving power for cationic enantiomers. It 
is a popular chiral additive in capillary electrophoresis (CE) but 
there are fewer reports of its application as a chiral additive in HPLC 
[22, 23]. However, there are no reports of RP-HPLC methods using S-
β-CD as CMPA for separating CIT enantiomers. One of the major 
challenges in chiral HPLC method development is to develop a cost 
effective method. In the current investigation, the first attempt was 
made to resolve CIT enantiomers on RP-HPLC using S-β-CD as CMPA. 
S-β-CD was synthesized in our laboratory at a cost approximately 40 
times lesser than that of the marketed product and was evaluated as 
a CMPA to resolve CIT enantiomers. The method was optimized, 
validated and applied to the pharmaceutical formulation. Resolution 
capability of marketed S-β-CD (S-β-CD1) was compared with that of 
S-β-CD synthesized in our laboratory (S-β-CD2). 
MATERIALS AND METHODS 
Chemicals and reagents 
Citalopram HBr and Escitalopram oxalate were received as gift 
samples from Shri C. B. Patel Research Centre, Mumbai, India. 
Sulfated beta cyclodextrin sodium salt (degree of substitution 7-11) 
was purchased from Sigma Aldrich, Mumbai, India and was also 
synthesized in our laboratory [unpublished observations]. β-CD was 
purchased from Jay Chem Marketing, Mumbai, India and 
hydroxypropyl beta cyclodextrin (HP-β-CD) was received as a gift 
sample from Gangwal Chemicals Pvt. Ltd., Mumbai, India. 
Escitalopram oxalate tablets (S citadep 5mg) manufactured by Cipla 
Ltd. India, was used for assay studies. Orthophosphoric acid (OPA) 
and HPLC grade methanol was purchased from S. D. Fine-Chemicals, 
Mumbai, India. KH2PO4
Instrumentation 
 and acetonitrile of HPLC grade were 
purchased from Merck, Mumbai, India. All other chemicals were of 
analytical reagent grade and used without further purification. 
Quartz double distilled water was used to prepare the mobile phase 
and diluents. Mobile phase was filtered through 0.45 µm nylon filter 
before use.  
FTIR spectra were recorded using Jasco V-460 plus FTIR 
spectrophotometer. KBr disc method was used to record the spectra. 
Enantiomeric separation was carried out on Jasco-1500 series HPLC 
system comprising of an isocratic pump, a rheodyne injector with a 
fixed loop of 20 µl and UV detector. Borwin software was used for 
data processing. The measurements were carried out under isocratic 
elution at ambient temperature. Kromasil C8 column (150 mm × 4.6 
mm, 5 µm) was used for the study. The flow rate was kept at 1 
ml/min and the injection volume was 20 µl. Detection was carried 
out at 240 nm.  
Preparation of stock and standard solution  
Stock solutions of racemic CIT and SCIT were prepared by dissolving 
50 mg of the drug in 50 ml methanol separately. Aliquots of 5 ml of 
the above solutions were diluted to 100 ml with methanol to provide 
50 µg/ml and these were further used for analysis with proper 
dilutions. Diluent used for final dilutions was methanol: 20 mM 
KH2PO4
Preparation of mobile phase 
 (65:35). 
The mobile phase was prepared by mixing methanol and 20 mM 
KH2PO4
Assay of tablet formulation 
 containing 12 mM S-β-CD at pH 3 (adjusted with 10% OPA) 
in the ratio of 35:65. The mobile phase was filtered through 0.45 µm 
nylon filter and sonicated for 5 min before use. 
Twenty tablets of escitalopram oxalate were weighed and crushed to 
a fine powder using a mortar and pestle. Powder equivalent to one 
tablet was accurately weighed and transferred to a 50 ml standard 
volumetric flask. Methanol: water (80:20, 40 ml) was added to the 
flask and sonicated for 30 min and volume was made up using the 
same solvent. An aliquot of the solution was filtered through 0.45 
µm nylon filter and transferred to a 10 ml standard volumetric flask 
to yield a concentration of 20 µg/ml. 
RESULTS AND DISCUSSION 
FT-IR analysis of sulfated beta cyclodextrin 
FTIR spectrum of S-β-CD1 was compared to that of S-β-CD2 (fig. 2). 
S-β-CD marketed by Sigma Aldrich mentions the degree of –OH 
groups substituted by the sulfate group to be 7–11 mol per mol beta 
cyclodextrin. The remaining hydroxyl groups will show O–H 
stretching at 3475 cm-1 and O–H bending at 1642 cm-1, which is 
clearly seen in both the spectra. A weak band at 2948 cm-1 is 
observed due to the stretching vibrations of C–H bond of –CH2 
groups. Band at 1158 cm-1 is observed due to the absorption of C–O 
stretching of C–OH bond and band at 941 cm-1 is attributed to the C–
O stretch of the glucose ring. Bands at 1233 cm-1 and 1057 cm-1
 
 are 
attributed to asymmetric stretching vibrations of S–O of S=O and S–
OH respectively [24]. All these bands were observed in both the 
spectra. Based on these similarities in the IR spectra of both the 
compounds it can be said that both the compounds are identical. 
Hence the study was carried out using the synthesized S-β-CD. 
 
Fig. 2: FT-IR spectra of Sulfated beta cyclodextrin a. S-β-CD1 b. 
S-β-CD2 
 
HPLC Method development 
For the method development, 10 µg/ml of racemic CIT was used. To 
achieve best separation between the enantiomers, various 
parameters affecting the resolution were evaluated.  
Effect of β-CD and its derivatives on resolution 
β-CD, HP-β-CD and S-β-CD2 were evaluated as chiral additives for 
enantiomeric resolution of CIT. No resolution was obtained with β-CD 
(10-15 mM) and HP-β-CD (10-20 mM) as chiral additives. Baseline 
resolution was obtained only with S-β-CD2 at a concentration of 10 
mM and above. This could be because the chiral recognition between 
the enantiomers and the charged cyclodextrins arise from several 
potential interactions, including electrostatic or ion pairing 
interactions as well as hydrophobic interactions and inclusion 
complexation [23]. Influence of S-β-CD2 in the concentration range of 
8-15 mM on the resolution was investigated in the mobile phase 
containing 20 mM phosphate buffer of pH 3 and 35 % methanol. As 
shown in fig. 3, with an increase in the concentration of chiral additive 
in the mobile phase, resolution increases, and retention time 
decreases. However, at 15 mM concentrations of S-β-CD2 in the mobile 
phase, the enantiomers eluted early, thereby showing a loss in 
resolution. Hence, 12 mM concentration of S-β-CD2 in the mobile 
phase was observed to be the optimum concentration giving a 
resolution of 2.6 with a run time of 16 min.  
Effect of pH on resolution 
Chiral recognition is based on the formation of a stable inclusion 
complex and hydrogen bonding interaction with the guest enantiomer 
and pH plays an important role in maintaining the stability of the 
complex. The influence of mobile phase pH in the range of 3-5 with 12 
mM chiral additive and 35% methanol was investigated. As shown in 
Deshpande et al. 
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fig. 4, with increase in pH of the mobile phase, retention time increased 
and resolution decreased. It was observed that the band broadened at 
higher pH values, resulting in lower resolution. Hence pH 3 was found 
to be the optimum pH for the analysis. 
 
Fig. 3: Effect of concentration of S-β-CD2 on resolution and 
retention time of CIT enantiomers. ●:  Resolution of CIT 
enantiomers. ■: Retention time of RCIT. ▲:  Retention tim e of 
SCIT. Chromatographic conditions: Mobile phase: Methanol: 20 
mM KH2PO4
Methanol and acetonitrile were evaluated as an organic component 
in the mobile phase for their effect on resolution.  
 containing S-β-CD2, pH 3 (35:65); Column: 
Kromasil C8 (150 mm × 4.6 mm, 5 µm); Flow rate: 1 ml/ min; λ: 
240 nm (n=3) 
 
Effect of organic component on resolution 
As seen in table 1, a resolution of 2.6 was obtained with a mobile 
phase containing 35% methanol. When methanol was replaced with 
acetonitrile in the same ratio, it was found that the enantiomers 
eluted early leading to the loss in resolution. When the ratio of 
acetonitrile was reduced, a resolution of ˃2 was observed only with 
longer retention times. As methanol showed good resolution in a 




Fig. 4: Effect of pH on resolution and retention time of CIT 
enantiomers. ●: Resolution of CIT enantiomers. ■: Retention 
time of RCIT. ▲:  Retention time of SCIT. Chromatographic 
conditions: Mobile phase: Methanol: 20 mM KH2PO4
 
 containing 
12 mM S-β-CD2 (35:65); Column: Kromasil C8 (150 mm × 4.6 
mm, 5 µm); Flow rate: 1 ml/ min; λ: 240 nm (n=3)
Table 1: Effect of methanol and acetonitrile on resolution. Other chromatographic conditions: Mobile phase: 20 mM KH2PO4
Organic component 
 containing 
12 mM S-β-CD2, pH 3; Column: Kromasil C8 (150 mm × 4.6 mm, 5 µm); Flow rate: 1 ml/ min; λ: 240 nm (n=3) 
% Composition in mobile phase Retention time (min); %RSD Resolution 
RCIT SCIT 
Methanol 40 8.9; 0.14 10.1; 0.42 1.8 
35 12.5; 0.26 14.7; 0.57 2.6 
30 23.4; 0.04 26.7; 0.24 3.1 
Acetonitrile 35 6.8; 0.41 7.4; 0.30 0.9 
25 16.4; 0.20 18.1; 0.10 1.9 
20 22.8; 0.04 24.2; 0.15 2.2 
15 28.7; 0.41 30.2; 0.08 2.9 
 
Effect of type and concentration of buffer on resolution 
Ammonium acetate, triethylammonium acetate (TEAA) and KH2PO4 
buffers were evaluated as an aqueous component in the mobile 
phase. The mobile phase containing ammonium acetate was unable 
to resolve the enantiomers. While in case of TEAA, broad peaks were 
observed, which resulted in lower resolution. Mobile phase with 
KH2PO4 buffer gave sharper peaks and good resolution. Further, the 
effect of 5, 10 and 20 mM phosphate buffer at pH 3 was investigated 
in mobile phase containing 12 mM S-β-CD2 and 35% methanol. It 
was observed that as KH2PO4 concentration in mobile phase 
increased, the peaks were sharper leading to better resolution. 
Hence, further studies were carried out using 20 mM KH2PO4
The optimized mobile phase for the enantiomeric separation of CIT 




containing 12 mM S-β-CD2 at pH 
3 (35:65) which showed resolution of 2.6 within a run time of 16 
min. S-β-CD1 was also evaluated as CMPA using the optimized 
conditions. As shown in fig. 5a, S-β-CD1 gave lower resolution of 
1.45. Thus, S-β-CD2 was found to be a better CMPA than S-β-CD1 
since it gave better resolution and lower retention times. A 
representative chromatogram using S-β-CD2 is shown in fig. 5b. 
After optimization of the parameters affecting the chromatographic 
separation of CIT enantiomers, the method was validated for 
linearity, limit of detection (LOD), limit of quantification (LOQ), 
precision, accuracy and robustness as per ICH guidelines.  
 
Fig. 5: Chromatogram of enantioseparation of CIT under 
optimized conditions. a. Using S-β-CD1 b. Using S-β-CD2. 
Chromatographic conditions: Mobile phase: Methanol: 20 mM 
KH2PO4 containing 12 mM S-β-CD2, pH 3 (35:65); Column: 
Kromasil C8 (150 mm × 4.6 mm, 5 µm); Flow rate: 1 ml/ min; λ: 
240 nm 
Deshpande et al. 




Peak area (y) was plotted against concentration (x) for both 
enantiomers. A good linearity was observed in the concentration range 
of 1 to 30 µg/ml of racemic CIT with a linear regression equation y = 
45556x-1695.7 for RCIT and y = 44746x+75.636 for SCIT with 
correlation coefficient (R2
LOD and LOQ were calculated based on standard deviation (SD) of 
response and slope. A series of dilute solutions of racemic CIT in the 
range of 0.25 – 1.25 µg/ml was injected and their response was 
plotted against concentration. The linear regression equation was 
found to be y = 48976x-33.438 and y = 48184x+149.56 for RCIT and 
SCIT, respectively. R
) of 0.9993 for both enantiomers. 
LOD & LOQ 
2
Precision 
 was found to be 0.9981 and 0.9977 for RCIT 
and SCIT, respectively. LOD and LOQ were calculated to be 0.0272 
and 0.0824 μg/ml for RCIT and 0.0303 and 0.0920 µg/ml for SCIT, 
respectively. 
Inter-day and intra-day precision was assessed by preparing 
racemic samples with 5, 10 and 15 µg/ml concentrations (2.5, 5 and 
7.5 µg/ml concentrations for each enantiomer) and analyzing them 
on two different days. Relative standard deviations (RSD) were 
calculated for the said concentration and were found to be less than 
2% (table 2). 
  
Table 2: Precision of CIT enantiomers in bulk drug samples (n=3) 
Concentration of racemic CIT (µg/ml) Intraday precision 
(µg/ml) mean±SD; %RSD  
Interday precision 
(µg/ml) mean±SD; %RSD  
RCIT SCIT RCIT SCIT 
5 2.57±0.01; 0.48 2.55±0.03; 1.02 2.54±0.02; 0.92 2.58±0.03; 1.27 
10 4.94±0.04; 0.74 4.96±0.06; 1.13 5.00±0.05; 1.03 4.98±0.04; 0.80 
15 7.35±0.04; 0.58 7.38±0.04; 0.51 7.30±0.06; 0.76 7.29±0.03; 0.38 
 
Table 3: Accuracy of citalopram enantiomers in bulk drug samples (n=3) 
Actual concentration of SCIT (µg/ml) Recovered Concentration of SCIT  
(µg/ml) mean±SD  
Mean % Recovery  
2.5 2.49±0.01 99.66  
5 5.06±0.06 101.19  
7.5 7.42±0.01 98.96  
 
Accuracy  
Accuracy of the method was determined by recovery studies. 2 
µg/ml solutions of racemic CIT were spiked with SCIT to obtain a 
concentration of 2.5, 5, and 7.5 µg/ml for SCIT. The results are 
shown in table 3. 
Robustness  
Robustness is the ability of the method to remain unaffected by small, 
deliberate changes in the parameters such as flow rate, pH and mobile 
phase composition. Chromatographic resolution of 10 µg/ml solutions of 
racemic CIT was used to evaluate the robustness of the method under 
altered conditions (pH±0.1 units, % methanol±1 ml, flow rate±0.1 
ml/min). Different batches of synthesized S-β-CDs were also evaluated. 
In all the cases, accuracy and precision were unaffected and the 
resolution was found to be 2˃.2. 
Application of the method 
The validated HPLC method was used for the quantitative analysis of 
CIT in bulk drug samples and commercial tablets. The assay 
chromatograms of bulk drug sample and tablet formulation are 
shown in fig. 6a and 6b, respectively. Assay of SCIT in the marketed 
formulation and bulk drug is presented in table 4 and 5, respectively.  
 
Fig. 6: Assay of Escitalopram in a. bulk drug b. formulation. 
Chromatographic conditions: Mobile phase, methanol: 20 mM 
KH2PO4
 
 containing 12 mM S-β-CD2 pH 3 (35:65,v/v); Kromasil C8 
(150 mm × 4.6 mm, 5 µm) column; flow rate 1 ml/ min; λ: 240 nm 
Table 4: Assay of SCIT in tablet formulation (n=3) 
Formulation Label claim (mg) Amount estimated  
(mg) mean±SD  
% Assay±% RSD  Resolution  
SCIT RCIT SCIT RCIT 
S citadep 5 5.07±0.03 0.04±3.7 × 10 101.45±0.7 -4 0.86±0.04 2.61  
 
Table 5: Assay of SCIT in bulk drug sample (n=3) 
Concentration of SCIT (µg/ml) Recovered concentration (µg/ml) mean±SD  % Assay±% RSD  Resolution  
SCIT RCIT SCIT RCIT 
10 9.93±0.02 0.11±0.001 99.3±0.24 1.11±1.13 2.59  
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A cost effective, simple and rapid RP-HPLC method was developed 
and validated for the enantiomeric separation of CIT on an achiral 
C8 column using synthesized S-β-CD as chiral mobile phase additive. 
The method was optimized for various parameters affecting 
resolution of the enantiomers. Resolution of 2.6 was achieved 
between CIT enantiomers within a run time of 16 min. The 
developed method was successfully applied to the quantitative 
determination of CIT enantiomers in bulk drug and tablet 
formulation. 
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